O-19 Comparison of imputation methods for missing immunohistochemical markers in a study of breast cancer prognosis  by Ali, Alaa M.G. et al.
We have assessed HER2 status in a large well-characterised
breast cancer series prepared as tissue microarray (n = 1858) using
IHC (HercepTest, DakoCytomation) and chromogenic ISH (CISH;
DuoCISH, DakoCytomation) in order to identify relationships with
clinico-pathological variables and patient outcome. None of these
cases have received anti-HER2 therapy.
There was excellent overall concordance between HercepTest
negative (scores 0/1+) and positive (3+) with CISH positive/nega-
tive (defined as HER2/Chr17 copy number ratio of P2; p < 0.001).
Twelve percent of cases were identified as HER2 positive (those
with 3+ HercepTest scores or 2+ with gene amplification). Of the
74 borderline HercepTest 2+ cases, 44 cases (59%) showed HER2
gene amplification. We identified that HercepTest 2+ non-ampli-
fied cases were not significantly different from those amplified
2+ or 3+ cases with respect to their clinical outcome (BCSS and
DFS).
The overall concordance between HercepTest and CISH analy-
sis for HER2 status was excellent. All HercepTest 2+ cases identi-
fied were observed to have poor outcomes similar to those
HercepTest 3+ cases regardless of gene amplification status. In
the current clinical environment, cases exhibiting IHC 2+ with
non-amplified HER2 gene status are not offered targeted HER2
therapy but do exhibit aggressive clinical behavioural characteris-
tics and therefore optimal treatment strategies for these patients
need to be determined.
doi:10.1016/j.ejcsup.2010.06.018
O-18 PARP1 EXPRESSION IN HORMONE ESTROGEN RECEPTOR
NEGATIVE BREAST CANCER: PREFERENTIAL EXPRESSION IN
BASAL-LIKE AND HER2-POSITIVE TUMOURS
Ahmed A. Benhasouna, Andrew R. Green, Des G. Powe,
Muhammad A. Aleskandarany, Emad A. Rakha, Ian O.
Ellis. Division of Pathology, Nottingham University Hospitals and
University of Nottingham, Nottingham, UK
Nuclear poly (ADP-ribose) polymerases (PARPs) are a family of
global monitor of chromatin structure and DNA damage repair.
The relative expression levels of PARP1 protein in estrogen recep-
tor negative (ER–ve) BC remain unclear. Therefore the aim of this
study was to investigate PARP1 protein expression in ER–ve BC
with relevance to molecular subtypes and disease outcome.
Methods: PARP1 protein expression was assessed, using immu-
nohistochemistry, in a well-characterised series of ER–ve primary
operable invasive BC cases (n = 251) with long term clinical follow-
up. Results were correlated with molecular and clinicopathologi-
cal parameters and patients’ outcome.
Results: PARP1 nuclear expression was classified as high or low
using a cut-off of 80 H-score, determined using X-Tile bio-infor-
matics software. One hundred and thirty five (53.8%) of the infor-
mative cases were classified showing high expression. Significant
positive correlation was found between PARP1 expression and
BRCA1 expression (p = 0.002) but no association was found with
p53. High PARP1 expression was observed in both basal-like
(HER2– and CK5/6 and or EGFR+) (60%) and HER2+ (64%) compared
with triple negative (TN) non-basal BC classes (45%). PARP1
expression was significantly associated with BC specific survival
(p = 0.01). When analysis was assessed by the molecular subtype,
the association of PARP1 expression with improved survival was
restricted to TN tumours.
Conclusion: We have observed a positive correlation between
PARP1 protein expression and BRCA1 expression. Although high
PARP1 expression is seen in ER–/HER+ and HER– tumours, its
association with survival was only found in the ER–/HER2– sub-
type. Thus, its targeted inhibition may particularly benefit
patients with TN BC.
doi:10.1016/j.ejcsup.2010.06.019
O-19 COMPARISON OF IMPUTATION METHODS FOR MISSING
IMMUNOHISTOCHEMICAL MARKERS IN A STUDY OF BREAST
CANCER PROGNOSIS
Alaa M.G. Ali a, S.-J. Dawson b,c, F. Blows b, E. Provenzano c,d,e, C.
Caldas b,c,d,e, Paul Pharoah a,b. aDepartment of Public Health and
Primary Care, Cambridge, UK. bDepartment of Oncology, University of
Cambridge, Cambridge, UK. cCancer Research UK Cambridge Research
Institute, Cambridge, UK. dCambridge Breast Unit, Addenbrooke’s
Hospital, Cambridge, UK. eNIHR Cambridge Biomedical Research
Centre, Cambridge, UK
Background: Tissue micro-arrays (TMA) are increasingly used to
generate data for studies of tumourmolecular phenotypehowever,
TMA data are particularly prone tomissingness. Avariety ofmeth-
ods to deal withmissing data are available; these have been exten-
sively evaluated using simulated data, but there has been no
empirical evaluations of these methods using real TMA data.
Methods: We pooled data from over 11,000 cases of invasive
breast cancer from five studies that collected information on
seven prognostic indicators including four molecular markers,
together with survival time data. We compared the results of a
multi-variate Cox regression using complete case analysis
(CCA), mean substitution (MS) and multiple imputation (MI). We
also performed an analysis in which missing data were simulated
under different assumptions.
Results: Over half the cases had data on at least one of the
seven variables and 10.5% had missing data on 4 or more. The
hazard ratio estimates based on multiple imputation and mean
substitution, were similar with similar standard errors. Hazard
ratio estimates and confidence intervals (Table). The results from
CCA were less precise (wider confidence limits). Accuracy of the
estimates was based on the simulated data with CCA having
the least accurate results.
Hazard ratios and confidence intervals using mean substitution
and multiple imputation.
Method ER status PR status HER2 status BCL2 status
Multiple
imputation
– HR (CIs)
0.43
(.35–54)
0.39
(.30–.50)
1.25
(1.13–1.40)
0.85
(.76–.96)
Mean
substitution
– HR (CIs)
0.40
(.32–.49)
0.37
(.29–.46)
1.31
(1.17–1.46)
0.82
(.74–.92)
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Conclusion: Mean substitution and multiple imputation per-
formed equally well in dealing with missing data generated by
TMA. Complete case analysis, the usual default method for statis-
tical software, resulted in the least accurate and least precise esti-
mates. Given the ease of implementing MS or MI, either approach
should be preferred to CCA.
doi:10.1016/j.ejcsup.2010.06.020
O-20 RATES OF GROWTH OF BREAST CANCER
R.W. Blamey, G. Ball, I.O. Ellis. NottinghamCity Hospital, Nottingham,
UK
Many estimates of growth rate have been published, mostly
theoretical. Here 3 clinically based measurements have been used
to produce curves of growth from inception (one cell) to 7 cm
diameter for each grade.
1. Screening effect – In a trial of screening an excess of tumours
were screen diagnosed by the end of the trial period. Time for
excess to present was calculated as G3 3–6 months, G2 1–
2 years and G1 5–6 years. The mean sizes by method of detec-
tion allowed volume doubling times to be calculated.
2. Occult time for inception to diagnosis – In young women there
is an excess of G3’s and few G1’s. Assuming that inception by
age is constant, graphs of actual detection rates at each age
and of expected allows calculation of the times for which each
grade is occult.
3. Time from primary treatment to death from breast cancer –
Plotting times to death gives medians for G3 167 months, G2
98 and G1 50.
4. As tumours enlarge mitoses become concentrated in the outer
2 mm ‘shell’.1
5. These observations allow curves of volume to be drawn for
each grade from single cell inception from which cell doubling
is assumed, giving a curve increasing logarithmically. From
10 mm diameter growth begins to slow logarithmically with
cell doubling restricted to the outer shell.
Reference:
1. Connor AJM et al. Breast 1997;6:171–6.
doi:10.1016/j.ejcsup.2010.06.021
O-21 DETECTION AND QUANTIFICATION OF MicroRNAs IN
LASER MICRODISSECTED FORMALIN-FIXED PARAFFIN EMBED-
DED (FFPE) BREAST CANCER TISSUES
Sarkawt M. Khoshnawa, Des G. Powea, Jorge S. Reis-Filho b, Ian O.
Ellis a, Andrew R. Green a. aDepartment of Histopathology, University
of Nottingham and Nottingham University Hospitals, Nottingham,
UK. bBreakthrough Breast Cancer Research Centre, Institute of Cancer
Research, London, UK
MicroRNAs (miRNAs) are a class of endogenous non-coding
RNAs that target protein coding mRNAs for cleavage or transla-
tional repression. Both profiling and functional studies demon-
strate deranged miRNA expression in many human cancers
including breast tumours. Research in this field is increasing
and the potential of miRNAs for being used in clinical settings
emphasises the need for sensitive detection techniques.
In this study, techniques for the analysis of miRNA expression
in microdissected FFPE breast cancer tissues were developed and
optimised. Full face sections from three invasive breast tumour
samples and different microdissected areas (1000–10 million ll2)
and section thickness (10–20 ll) were analysed. Total RNA was
extracted using commercially available RNA extraction kits
(miRNeasy FFPE Kit, Qiagen; RecoverAlle Total Nucleic Acid Isola-
tion Kit for FFPE, Ambion; PureLink FFPE RNA Isolation Kit, Invit-
rogen). Three miRNAs (miR21: highly expressed, miR-29c:
intermediately expressed, and miR-127: low expression in breast
cancer) extracted from both gross and microdissected invasive
breast cancer tissues were quantified using real-time PCR.
The PureLink kit produced largest quantities of total RNA from
FFPE breast tumours. All three miRNA (21, 29c and 127) were suc-
cessfully detected by real-time PCR and levels of sensitivity were
comparable between extraction methods. Our data showed that
relative miRNA levels gradually decreased with diminishing
amounts of microdissected tissue used but reliable miRNA quan-
tification was obtained using at least 5 million ll2 from 20 ll thick
FFPE breast tissue sections.
In contrast to previously published results, quantity of miRNA
detected in breast tissue samples depends on the amount of tis-
sue used, and cannot be performed reliably from one or a few
cells.
doi:10.1016/j.ejcsup.2010.06.022
O-22 A NOVEL ARTIFICIAL NEURAL NETWORK BASED ALGO-
RITHM TO ANALYSE THE INTERACTION PATTERNS EXISTING IN
GENE MICROARRAYS: AN APPLICATION TO BREAST CANCER
GENOMIC DATA
Christophe Lemetre, Lee James Lancashire, Graham Roy Ball.
Nottingham Trent University, UK
Genomic array technologies, by allowing the assessment of
the level of expression of thousands of genes simultaneously in
the same experiment, have brought the hope to identify new bio-
markers related to particular outcome in disease. The majority of
the research conducted to date with gene microarrays has only
been focusing on this biomarker discovery. However, these arrays
hold the inherent information of gene co-expression patterns and
only few groups have focused their attention toward deciphering
such network of interactions and regulation.
We present here a novel approach based on Artificial Neural
Network technology to further analyse the data extracted from
gene array experiments. This approach has been applied to a
well-known breast cancer dataset publicly available.1 The results
showed interesting patterns of interactions or gene regulation,
and some of them could be confirmed by alternative methods,
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